RNA Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas

Preço

$12.84

Capitalização de Mercado

$10.91B

P/E (TTM)

-14.5

EPS (TTM)

$-4.97

Receita (TTM)

$19M

Rendimento div.

—

ROE

-47.5%

Dívida/Capital

—

Intervalo 52 Semanas

$12 – $73

RNA Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização

Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS

Receita e Lucro Líquido $19M

2018-12-31 → 2025-12-31

EPS $-4.97

2020-12-31 → 2025-12-31

Fluxo de caixa livre $-664M

2020-12-31 → 2025-12-31

Margens -3650.4%

Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?

Métrica

Tendência de 5 anos

RNA

Mediana de Pares

P/E (TTM)

-14.5

2.4

P/S (TTM)

581.5

15.2

P/B

6.5

1.4

Price / FCF (Preço / FCF)

-16.4

—

Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC

Métrica

Tendência de 5 anos

RNA

Mediana de Pares

Operating Margin (Margem Operacional)

-3977.3%

—

Net Profit Margin (Margem de Lucro Líquido)

-3650.4%

-946.2%

ROA

-38.9%

-52.8%

ROE

-47.5%

-60.2%

ROIC

-44.2%

—

Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial

Métrica

Tendência de 5 anos

RNA

Mediana de Pares

Current Ratio (Índice de liquidez corrente)

9.2

7.4

Quick Ratio (Índice de Liquidez Seca)

2.0

—

Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos

Métrica

Tendência de 5 anos

RNA

Mediana de Pares

Revenue YoY (Receita Ano a Ano)

72.1%

—

Revenue CAGR 3Y (CAGR Receita 3A)

26.7%

—

Revenue CAGR 5Y (CAGR Receita 5A)

22.5%

—

Métricas por Ação EPS, valor patrimonial por ação, fluxo de caixa por ação, dividendo por ação

Métrica

Tendência de 5 anos

RNA

Mediana de Pares

EPS (Diluted) (EPS (Diluído))

$-4.97

—

Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber

Métrica

Tendência de 5 anos

RNA

Mediana de Pares

RNA Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta

COMPRA 5 analistas

Compra forte 1 20,0%
Compra 3 60,0%
Manter 1 20,0%
Venda 0 0,0%
Venda forte 0 0,0%

Preço-alvo de 12 meses

2 analistas · 2026-05-20

Mín $25.00

Máx $25.00

Alvo mediano $25.00 +94,8%

Alvo médio $25.00 +94,8%

Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados

Surpresa Média

0.09%

Período	EPS Actual	EPS est.	Surpresa
31 de Março de 2026	$-0.97	$-1.06	0.09%

Comparação com pares Métricas chave vs pares do setor

Ticker	Capitalização de Mercado	P/E	Receita YoY	Margem Líquida	ROE	Margem Bruta
RNA	$10.91B	-14.5	72.1%	-3650.4%	-47.5%	—
FHTX	$306M	-4.6	36.8%	-240.3%	80.2%	—
NERV	$174M	-0.1	—	—	339.5%	—
FATE	$113M	-0.9	-51.2%	-2051.1%	-58.2%	—
WHWK	$114M	-7.3	-72.5%	-288.3%	-13.4%	—
IKT	$270M	-4.2	111.0%	-1299.0%	-38.2%	—
KROS	$398M	8.9	—	35.7%	17.2%	—
BDTX	$139M	6.2	—	31.9%	18.3%	—
VYGR	$232M	-1.9	-49.5%	-296.5%	-54.4%	—
UNCY	$128M	-3.5	-29.0%	—	-113.9%	—

Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa

Demonstração de Resultados 15

Dados anuais de Demonstração de Resultados para RNA
Métrica	2025	2024	2023	2022	2022	2021	2020	2019
Revenue	$19M	$11M	$10M	$9M	·	$9M	$7M	$2M
R&D Expense	$559M	$304M	$191M	$150M	·	$101M	$38M	$15M
SG&A Expense	$206M	$86M	$54M	$38M	·	$26M	$13M	$5M
Operating Expenses	$765M	$390M	$245M	$188M	·	$127M	$51M	$20M
Operating Income	$-746M	$-379M	$-236M	$-179M	·	$-118M	$-44M	$-17M
Interest Expense	·	·	·	$0	·	$0	$209.0K	$7M
Other Non-op	$-2M	$-248.0K	$-594.0K	$-57.0K	·	$-62.0K	$-75.0K	$0
Pretax Income	$-685M	$-322M	$-212M	·	·	·	·	·
Income Tax	$0	$0	$0	$0	·	$0	$0	$0
Net Income	$-685M	$-322M	$-212M	$-174M	·	$-118M	$-44M	$-25M
EPS (Basic)	$-4.97	$-2.89	$-2.91	$-3.34	·	$-2.85	$-2.05	·
EPS (Diluted)	$-4.97	$-2.89	$-2.91	$-3.34	·	$-2.85	$-2.05	·
Shares (Basic)	137,710,000	111,582,000	73,012,000	52,162,000	·	41,428,000	21,663,000	·
Shares (Diluted)	137,710,000	111,582,000	73,012,000	52,162,000	·	41,428,000	21,663,000	·
EBITDA	$-746M	$-379M	$-236M	$-179M	·	$-118M	$-44M	·

Balanço Patrimonial 24

Dados anuais de Balanço Patrimonial para RNA
Métrica	2025	2024	2023	2022	2022	2021	2020	2019
Cash & Equivalents	$383M	$220M	$185M	$340M	·	$320M	$321M	$95M
Short-term Investments	·	·	·	·	·	$85M	$7M	·
Receivables	·	$0	$1M	$2M	·	·	·	·
Prepaid Expense	$102M	$41M	$16M	$12M	·	$6M	·	·
Other Current Assets	$53M	$19M	·	$2M	·	·	·	·
Current Assets	$1.80B	$1.54B	$611M	$623M	·	$411M	$332M	$96M
PP&E (Net)	$23M	$13M	$8M	$6M	·	$5M	$1M	$631.0K
PP&E (Gross)	$35M	$21M	$14M	$9M	·	$7M	$3M	$2M
Accum. Depreciation	$12M	$8M	$5M	$3M	·	$2M	$2M	$2M
Other Non-current Assets	$82M	$521.0K	$301.0K	$598.0K	·	$599.0K	$47.0K	$600.0K
Total Assets	$1.96B	$1.56B	$629M	$639M	·	$428M	$334M	$97M
Accounts Payable	$12M	$8M	$9M	$5M	·	$3M	$8M	$2M
Current Liabilities	$195M	$98M	$81M	$52M	·	$30M	$15M	$10M
Capital Leases	$45M	$3M	$6M	$8M	·	$10M	$938.0K	$393.0K
Other Non-current Liabilities	·	·	·	·	·	·	·	$45.0K
Total Liabilities	$269M	$139M	$128M	$61M	·	$46M	$28M	$28M
Long-term Debt	·	·	·	·	·	·	·	$5M
Common Stock	$15.0K	$12.0K	$8.0K	$7.0K	·	$5.0K	$4.0K	$0
Paid-in Capital	·	·	·	$939M	·	$566M	$373M	$-43M
Retained Earnings	$-1.58B	$-893M	$-571M	$-359M	·	$-185M	$-67M	$-22M
AOCI	$3M	$3M	$125.0K	$-3M	·	$-187.0K	$-5.0K	·
Stockholders' Equity	$1.69B	$1.42B	$501M	$578M	$374M	$381M	$306M	$-65M
Liabilities + Equity	$1.96B	$1.56B	$629M	$639M	·	$428M	$334M	$97M
Shares Outstanding	151,205,000	119,893,000	79,275,000	69,768,000	52,081,000	47,754,000	37,569,000	2,989,000

Fluxo de Caixa 10

Dados anuais de Fluxo de Caixa para RNA
Métrica	2025	2024	2023	2022	2022	2021	2020	2019
Stock-based Comp	$98M	$51M	$38M	$27M	·	$17M	$4M	$406.0K
Operating Cash Flow	$-650M	$-301M	$-119M	$-136M	·	$-95M	$-37M	$2M
CapEx	$13M	$7M	$4M	$3M	·	$4M	$1M	$235.0K
Investing Cash Flow	$-38M	$-854M	$-130M	$-190M	·	$-83M	$-8M	$-235.0K
Net Debt Issued	·	·	·	$0	·	$0	$-5M	·
Stock Issued	$837M	$762M	$61M	$345M	$82M	$175M	$274M	·
Net Stock Activity	$837M	$762M	$61M	$345M	$82M	$20M	·	·
Financing Cash Flow	$851M	$1.19B	$94M	$346M	·	$176M	$272M	$89M
Net Change in Cash	$163M	$37M	$-155M	$20M	·	$-1M	$227M	$91M
Free Cash Flow	$-664M	$-308M	$-123M	$-139M	·	$-99M	$-38M	·

Lucratividade 7

Dados anuais de Lucratividade para RNA
Métrica	2025	2024	2023	2022	2022	2021	2020	2019
Operating Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	·	-1265.8%	-652.4%	·
Net Margin	-3650.4%	-2957.7%	-2219.9%	-1886.3%	·	-1265.4%	-653.5%	·
Pretax Margin	-3650.4%	·	·	·	·	·	·	·
EBITDA Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	·	-1265.8%	-652.4%	·
ROA	-38.9%	-29.4%	-33.5%	-32.6%	·	-31.0%	-20.6%	·
ROE	-47.5%	-22.0%	-41.7%	-36.4%	·	-30.4%	-14.2%	·
ROIC	-44.2%	·	·	·	·	·	·	·

Liquidez e Solvência 3

Dados anuais de Liquidez e Solvência para RNA
Métrica	2025	2024	2023	2022	2022	2021	2020	2019
Current Ratio	9.2	15.7	7.6	12.0	·	13.9	22.7	·
Quick Ratio	2.0	2.2	2.3	6.6	·	13.7	22.5	·
Interest Coverage	·	·	·	·	·	·	-211.9	·

Eficiência 2

Dados anuais de Eficiência para RNA
Métrica	Tendência	2025	2024	2023	2022	2022	2021	2020	2019
Asset Turnover		0.0	0.0	0.0	0.0	·	0.0	0.0	·
Receivables Turnover		·	19.7	5.5	·	·	·	·	·

Por Ação 5

Dados anuais de Por Ação para RNA
Métrica	2025	2024	2023	2022	2022	2021	2020	2019
Book Value / Share	$11.17	$11.89	$6.32	$8.29	·	$7.99	$8.15	·
Revenue / Share	$0.14	$0.10	$0.13	$0.18	·	·	·	·
Cash Flow / Share	$-4.72	$-2.70	$-1.63	$-2.61	·	·	·	·
Cash / Share	$2.53	$1.83	$2.33	$4.88	·	$6.71	$8.56	·
EPS (TTM)	$-4.97	$-2.89	$-2.91	$-3.34	$-3.01	$-2.85	$-2.05	·

Taxas de Crescimento 3

Dados anuais de Taxas de Crescimento para RNA
Métrica	2025	2024	2023	2022	2022	2021	2020	2019
Revenue YoY	72.1%	14.0%	3.6%	-1.1%	·	37.4%	·	·
Revenue CAGR 3Y	26.7%	5.3%	12.1%	·	·	·	·	·
Revenue CAGR 5Y	22.5%	·	·	·	·	·	·	·

Avaliação (TTM) 10

Dados anuais de Avaliação (TTM) para RNA
Métrica	2025	2024	2023	2022	2022	2021	2020	2019
Revenue TTM	$19M	$11M	$10M	$9M	$9M	$9M	$7M	·
Net Income TTM	$-685M	$-322M	$-212M	$-174M	$-136M	$-118M	$-44M	·
Market Cap	$10.91B	$3.49B	$717M	$1.55B	·	$1.14B	$959M	·
P/E	-14.5	-10.1	-3.1	-6.6	-4.8	-8.3	-12.4	·
P/S	581.5	319.9	75.0	167.8	·	121.7	141.3	·
P/B	6.5	2.4	1.4	2.7	·	3.0	3.1	·
P / Tangible Book	6.5	2.4	1.4	2.7	·	3.0	3.1	·
P / Cash Flow	-16.8	-11.6	-6.0	-11.4	·	-12.0	-25.8	·
P / FCF	-16.4	-11.3	-5.8	-11.1	·	-11.5	-25.1	·
Earnings Yield	-6.9%	-9.9%	-32.1%	-15.0%	-20.7%	-12.0%	-8.0%	·

Demonstração de Resultados 12

Dados trimestrais de Demonstração de Resultados para RNA
Métrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	$860.0K	$12M	$4M	$2M	$3M	$2M	$2M	$4M	$2M	$3M	$2M	$2M	$3M	$2M	$2M	$2M
R&D Expense	$167M	$155M	$138M	$99M	$96M	$77M	$64M	$67M	$53M	$48M	$43M	$48M	$46M	$37M	$40M	$28M
SG&A Expense	$89M	$46M	$37M	$34M	$28M	$23M	$21M	$14M	$16M	$14M	$12M	$12M	$10M	$10M	$9M	$9M
Operating Expenses	$255M	$201M	$175M	$133M	$124M	$100M	$85M	$81M	$69M	$61M	$55M	$60M	$56M	$47M	$48M	$36M
Operating Income	$-254M	$-189M	$-171M	$-132M	$-121M	$-98M	$-83M	$-77M	$-67M	$-59M	$-53M	$-58M	$-53M	$-45M	$-46M	$-34M
Other Non-op	$-477.0K	$-380.0K	$-651.0K	$-435.0K	$201.0K	$-232.0K	$-116.0K	$-101.0K	$-105.0K	$-13.0K	$-162.0K	$-314.0K	$-18.0K	$-12.0K	$-2.0K	$-25.0K
Net Income	$-237M	$-174M	$-157M	$-116M	$-102M	$-80M	$-71M	$-69M	$-60M	$-52M	$-47M	$-52M	$-50M	$-44M	$-46M	$-34M
EPS (Basic)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
EPS (Diluted)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
Shares (Basic)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
Shares (Diluted)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
EBITDA	·	$-189M	$-171M	$-132M	·	$-98M	$-83M	$-77M	·	$-59M	$-53M	$-58M	·	$-45M	·	$-34M

Balanço Patrimonial 21

Dados trimestrais de Balanço Patrimonial para RNA
Métrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Cash & Equivalents	$383M	$350M	$244M	$254M	$220M	$370M	$576M	$471M	·	$86M	$154M	$119M	·	$144M	$125M	$139M
Short-term Investments	·	·	·	·	·	·	·	·	·	·	·	·	·	$262M	$273M	$258M
Receivables	·	·	·	·	·	$0	$0	$2M	·	·	$1M	·	·	·	·	·
Prepaid Expense	$102M	$90M	$67M	$55M	$41M	$33M	$30M	$19M	·	·	$11M	·	·	·	·	·
Other Current Assets	$53M	$60M	$43M	·	$19M	·	·	·	·	·	$6M	·	·	·	·	·
Current Assets	$1.80B	$1.97B	$1.25B	$1.43B	$1.54B	$1.62B	$1.33B	$934M	·	$555M	$595M	$597M	·	$414M	$404M	$405M
PP&E (Net)	$23M	$22M	$21M	$16M	$13M	$9M	$8M	$9M	·	$8M	$8M	$8M	·	$6M	$6M	$5M
PP&E (Gross)	$35M	$32M	$30M	$24M	$21M	$17M	$15M	$15M	·	$13M	$12M	$11M	·	$9M	$9M	$7M
Accum. Depreciation	$12M	$10M	$10M	$9M	$8M	$7M	$7M	$6M	·	$5M	$4M	$4M	·	$3M	$2M	$2M
Other Non-current Assets	$82M	$91M	$91M	$739.0K	$521.0K	$318.0K	$364.0K	$425.0K	·	$344.0K	$424.0K	$474.0K	·	$523.0K	$415.0K	$548.0K
Total Assets	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Accounts Payable	$12M	$10M	$4M	$7M	$8M	$8M	$9M	$2M	·	$6M	$6M	$4M	·	$26M	$21M	$19M
Current Liabilities	$195M	$170M	$135M	$85M	$98M	$91M	$84M	$75M	·	$49M	$45M	$48M	·	$43M	$34M	$31M
Capital Leases	$45M	$46M	$1M	$2M	$3M	$4M	$5M	$5M	·	$7M	$6M	$7M	·	$8M	$9M	$9M
Total Liabilities	$269M	$248M	$176M	$130M	$139M	$137M	$126M	$121M	·	$56M	$52M	$55M	·	$54M	$46M	$45M
Common Stock	$15.0K	$15.0K	$12.0K	$12.0K	$12.0K	$12.0K	$11.0K	$10.0K	·	$7.0K	$7.0K	$7.0K	·	$5.0K	$5.0K	$5.0K
Retained Earnings	$-1.58B	$-1.34B	$-1.17B	$-1.01B	$-893M	$-791M	$-710M	$-640M	·	$-510M	$-458M	$-411M	·	$-308M	$-264M	$-219M
AOCI	$3M	$2M	$2M	$3M	$3M	$7M	$-453.0K	$-464.0K	·	$-2M	$-3M	$-2M	·	$-3M	$-3M	$-2M
Stockholders' Equity	$1.69B	$1.89B	$1.19B	$1.33B	$1.42B	$1.50B	$1.22B	$831M	$501M	$517M	$559M	$559M	$578M	$377M	$374M	$376M
Liabilities + Equity	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Shares Outstanding	151,205,000	146,771,000	120,778,000	120,512,000	119,893,000	118,900,000	109,266,000	95,594,000	79,275,000	74,101,000	74,070,000	70,813,000	69,768,000	54,446,000	52,081,000	49,281,000

Fluxo de Caixa 9

Dados trimestrais de Fluxo de Caixa para RNA
Métrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Stock-based Comp	$43M	$19M	$18M	$18M	$14M	$14M	$13M	$10M	$10M	$10M	$9M	$9M	$7M	$7M	$7M	$6M
Operating Cash Flow	$-170M	$-156M	$-200M	$-125M	$-100M	$-66M	$-65M	$-70M	$17M	$-37M	$-50M	$-49M	$-39M	$-32M	$-36M	$-30M
CapEx	$6M	$712.0K	$3M	$4M	$4M	$2M	$531.0K	$915.0K	$863.0K	$923.0K	$622.0K	$2M	$850.0K	$-107.0K	$1M	$758.0K
Investing Cash Flow	$207M	$-588M	$185M	$157M	$-64M	$-482M	$-275M	$-33M	$51M	$-31M	$46M	$-196M	$-8M	$11M	$-18M	$-175M
Stock Issued	$-538.0K	$837M	$0	$0	$-500.0K	$324M	$433M	$6M	$0	$0	$38M	$22M	$243M	$39M	$38M	$24M
Net Stock Activity	·	·	·	$0	·	·	·	$6M	·	·	·	$22M	·	·	·	$24M
Financing Cash Flow	$-5M	$850M	$4M	$2M	$14M	$342M	$447M	$389M	$32M	$40.0K	$39M	$23M	$244M	$40M	$39M	$24M
Net Change in Cash	$32M	$106M	$-10M	$34M	$-150M	$-206M	$107M	$286M	$99M	$-68M	$35M	$-222M	$197M	$19M	$-14M	$-181M
Free Cash Flow	·	·	·	$-129M	·	·	·	$-71M	·	·	·	$-51M	·	·	·	$-30M

Lucratividade 5

Dados trimestrais de Lucratividade para RNA
Métrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Operating Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
Net Margin	·	-1398.3%	-4089.3%	-7360.0%	·	-3441.7%	-3461.8%	-1943.4%	·	-1858.0%	-2030.4%	-2346.3%	·	-1756.6%	·	-1907.2%
EBITDA Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
ROA	·	-9.2%	-11.6%	-9.6%	·	-7.3%	-7.2%	-8.8%	·	-10.4%	-9.1%	-10.1%	·	-10.2%	·	-9.3%
ROE	·	-10.3%	-13.0%	-10.7%	·	-8.0%	-8.0%	-9.9%	·	-11.7%	-10.1%	-11.2%	·	-11.3%	·	-10.3%

Liquidez e Solvência 2

Dados trimestrais de Liquidez e Solvência para RNA
Métrica	Tendência	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Current Ratio		·	11.6	9.3	16.9	·	17.8	15.8	12.5	·	11.4	13.1	12.4	·	9.7	·	13.1
Quick Ratio		·	2.1	1.8	3.0	·	4.1	6.8	6.3	·	1.8	3.4	2.5	·	9.5	·	12.8

Eficiência 2

Dados trimestrais de Eficiência para RNA
Métrica	Tendência	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Asset Turnover		·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	·	0.0
Receivables Turnover		·	·	·	·	·	·	3.5	4.5	·	·	3.9	·	·	·	·	·

Por Ação 5

Dados trimestrais de Por Ação para RNA
Métrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Book Value / Share	·	$12.85	$9.87	$11.03	·	$12.64	$11.17	$8.69	·	$6.98	$7.55	$7.89	·	$6.92	·	$7.62
Revenue / Share	·	$0.09	$0.03	$0.01	·	$0.02	$0.02	$0.04	·	$0.04	$0.03	$0.03	·	$0.05	·	·
Cash Flow / Share	·	·	·	$-0.97	·	·	·	$-0.81	·	·	·	$-0.70	·	·	·	·
Cash / Share	·	$2.39	$2.02	$2.11	·	$3.11	$5.27	$4.93	·	$1.16	$2.08	$1.68	·	$2.64	·	$2.83
EPS (TTM)	·	$-4.03	$-3.41	$-2.99	·	$-2.80	$-2.81	$-2.90	·	$-2.93	$-3.14	$-3.19	·	$-3.13	·	·

Avaliação (TTM) 10

Dados trimestrais de Avaliação (TTM) para RNA
Métrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue TTM	·	$20M	$10M	$9M	·	$11M	$11M	$11M	·	$10M	$9M	$9M	·	$9M	·	$9M
Net Income TTM	·	$-528M	$-424M	$-336M	·	$-272M	$-239M	$-221M	·	$-195M	$-189M	$-176M	·	$-153M	·	$-114M
Market Cap	·	$6.39B	$3.43B	$3.56B	·	$5.46B	$4.46B	$2.44B	·	$473M	$821M	$1.09B	·	$889M	·	$910M
P/E	·	-10.8	-8.3	-9.9	·	-16.4	-14.5	-8.8	·	-2.2	-3.5	-4.8	·	-5.2	·	·
P/S	·	316.1	350.0	374.6	·	508.4	416.3	223.6	·	48.0	89.2	125.1	·	103.2	·	98.2
P/B	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Tangible Book	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Cash Flow	·	·	·	-28.5	·	·	·	-34.7	·	·	·	-22.2	·	·	·	-30.8
P / FCF	·	·	·	-27.7	·	·	·	-34.2	·	·	·	-21.4	·	·	·	-30.0
Earnings Yield	·	-9.2%	-12.0%	-10.1%	·	-6.1%	-6.9%	-11.4%	·	-45.9%	-28.3%	-20.8%	·	-19.2%	·	·

Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos

Demonstração de Resultados

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Receita	$19M	$11M	$10M	$9M	$9M
Margem Operacional %	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%
Lucro líquido	$-685M	$-322M	$-212M	$-174M	$-118M
EPS Diluído	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85

Balanço Patrimonial

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Índice de liquidez corrente	9.2	15.7	7.6	12.0	13.9
Índice de Liquidez Seca	2.0	2.2	2.3	6.6	13.7

Fluxo de Caixa

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Fluxo de caixa livre	$-664M	$-308M	$-123M	$-139M	$-99M

Últimas notícias Notícias recentes mencionando esta empresa

CureVac processa Moderna por infração de patente de vacinas COVID-19 Yahoo Finance · 3 semanas, 3 dias atrás

Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos

📊

Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.

Sua seleção é salva e acompanha você em todos os tickers.

RNA Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas

RNA Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização

Médias móveis e sobreposições

Volume

Osciladores

Momento e tendência

Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS

Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?

Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC

Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial

Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos

Métricas por Ação EPS, valor patrimonial por ação, fluxo de caixa por ação, dividendo por ação

Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber

RNA Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta

Preço-alvo de 12 meses

Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados

Comparação com pares Métricas chave vs pares do setor

Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa

Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos

Últimas notícias Notícias recentes mencionando esta empresa

Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos